Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 21, 2025 09:35 ET | Source: Transparency Market Research

Cell Therapy Market Outlook 2034: Rapid Growth Projected with a 20.8% CAGR, Set to Reach US$ 44.6 Billion, Latest Report by TMR

Wilmington, Delaware, Transparency Market Research Inc. –, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The cell therapy market is rapidly evolving, driven by groundbreaking advancements in medical research...
February 24, 2023 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
May 11, 2021 08:00 ET | Source: Acepodia USA

Acepodia Appoints Thorsten Graef, M.D., Ph.D., as Chief Medical Officer and Michael Brock as Chief Strategy Officer

SAN MATEO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointments...
November 09, 2018 08:00 ET | Source: Nkarta

Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model

NK cell potency and persistence significantly improved using cell engineering technology60% increase in cytotoxicity observed with Nkarta NK cells relative to control NK cellsSingle in vivo...
July 09, 2018 08:00 ET | Source: Nkarta

Nkarta Therapeutics Expands Management Team and Establishes New Corporate Headquarters

SOUTH SAN FRANCISCO, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
June 11, 2018 08:00 ET | Source: Nkarta

Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology From National University of Singapore and St. Jude Children’s Research Hospital

SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
March 01, 2018 14:05 ET | Source: Nkarta

Nkarta Therapeutics Appoints Veteran Executive Paul Hastings as CEO to Lead Next Phase of Growth

SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing natural killer (NK) immune cells to fight cancer, announced that...
November 03, 2016 16:59 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...